Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Completed 16Terminated 6Unknown 2

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Melanoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 106Cyclophosphamide 97Cisplatin 75Carboplatin 66Fluorouracil 64Etoposide 61Doxorubicin 60Chemotherapy, Adjuvant 60Vincristine 56Peripheral Blood Stem Cell Transplantation 48Filgrastim 47Paclitaxel 46Gemcitabine 44Cytarabine 41Neoadjuvant Therapy 40Leucovorin 40Docetaxel 35Melphalan 31Oxaliplatin 29Methotrexate 29Ifosfamide 25Gene Expression Profiling 25Amplified Fragment Length Polymorphism Analysis 24Immunohistochemistry 23Dexamethasone 22Irinotecan 21aldesleukin 20Prednisolone 20Interferon-alpha 20Tamoxifen 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × NIH × oblimersen × Clear all
NCT00030641 2014-01-06

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2/3 Unknown
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00070343 2014-01-06

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

National Cancer Institute (NCI)

Phase NA Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡